October 2, 2025 4:48pm

Government’s 2nd day “turn-off”, a “normal” market and sector mixed forward

As we celebrate observance of Yom Kippur

We seem to be always waiting for … something i.ie., anything!

Reiterating, “uncle algo and his electronic trading dwarfs” are scheming to sell some

Never leave an investor uninformed!  

Remember, “The sector is still what it is, until it isn’t, even if it doesn’t seem to be, it yet will be.” 

Thursday’s RMi pre-open: Wavering … https://www.regmedinvestors.com/articles/14133

 

Thursday: The Dow closed UP +78.62 points or +0.17%, the S&P closed UP +4.15 points or +0.06% while the Nasdaq closed UP +88.894 points or +0.39%

  • Theme of the session: shrugging-off concerns of 2nd day government shutdown

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy

  • An economic data blackout
  • Claims were “expected” to rise modestly to 224,000 after 2 straight weeks of unexpected declines to 218,000, according to Econoday estimates. And factory orders were expected to rise 1.4% in August.
  • Private data from the firm Challenger, Gray & Christmas released Thursday found hiring plans at their lowest level since 2009, even as layoffs fell. The report provided more evidence of the softening "low hire, low fire" labor market after Wednesday's ADP report. Investors remain near-unanimous on bets for a cut at the Fed's next meeting.

Thursday’s (my) 40-company covered sector’s advance/decline line opened positive with 22 incliners, 17 decliners and 1 flat ending with a positive close of 26 incliners, 13 decliners and 1 flat

Metrics:  Thursday, the RUT +16.14 points or +0.66%, the IBB was up +0.75%, the XLV was down -0.22%, the XBI was up +1.20% while the VIX was up +0.0.37 points or +2.27% at 16.66

 

Q4 – 2 positive closes

Q3 – September - 1 holiday, 9 negative and 12 positive closes; August - 12 negative and 9 positive closes; July - 1 market holiday, 13 positive and 9 negative closes

 

Thursday Closing UP (10 of 26) 

  • CRISPR Therapeutics (CRSP +$6.66 after Wednesday’s +$1.35, Tuesday’s +$1.04 and Monday’s +$2.10),
  • Vertex (VRTX +$4.64 after Wednesday’s +$12.57, Tuesday’s -$3.67 and Monday’s +$9.58),
  • Sarepta Therapeutics (SRPT +$3.03),
  • Ionis Pharmaceuticals (IONS +$2.60),
  • BioNTech (BNTX +$2.30 after Wednesday’s +$3.59 and Tuesday’s +$0.52),
  • Intellia Therapeutics (NTLA +$1.68 after Wednesday’s +$1.49),
  • Beam Therapeutics (BEAM +$1.46 after Wednesday’s -$0.14),
  • Prime Medicine (PRME +$1.08),
  • Ultragenyx Pharmaceuticals (RARE +$0.91 after Wednesday’s -$0.09, Tuesday’s -$0.28 and Monday’s +$1.28),
  • Regenxbio (RGNX +$0.08),

Flat (1)

  • Harvard Apparatus RT (OTCQB: HRGN -$0.07 after Tuesday’s $0.00),

Thursday’s Closing DOWN (13 of 13): 

  • Lenz Therapeutics (LENZ closed -$0.73 after Wednesday’s +$2.47, Tuesday’s +$1.69 and Monday’s +$2.86),
  • uniQure NV (QURE -$0.49 after Wednesday’s -$3.38, Tuesday’s -$1.03 and Monday’s +$5.09),
  • Arrowhead Pharmaceuticals (ARWR -$0.41),
  • BioLife Solutions (BLFS -$0.22 after Wednesday’s +$0.62 and Tuesday’s +$0.99),
  • Solid Biosciences (SLDB -$0.13 after Wednesday’s -$0.30),
  • Supernus Therapeutics (SUPN -$0.08),
  • Fate Therapeutics (FATE -$0.04),
  • Caribou Biosciences CRBU -$0.03),
  • Brainstorm Cell Therapeutics (BCLI -$0.02),
  • Wave Life Sciences (WVE -$0.01 and Wednesday’s -$0.29),
  • MiMedx (MDXG -$001 after Wednesday’s -$0.15)

 

The Bottom Line: More of the … WHYs …

Markets have so far been nonplussed by the US government shutdown, today celebrates Yom Kippur; Democratic bills should “atone” for their grievous mistake in leading a “shakedown” on the American people…

  • After failing to agree on federal spending, suspending non-essential government operations and putting hundreds of thousands of federal employees at risk of furlough.
  • The release of September jobs data has been delayed — originally expected out on Friday — due to the US government's shutdown.

October: understand the “flow” …

  • 10/2 - Thursday closed positive with 26 positive, 13 negative and 1 flat
  • 10/1 – Wednesday closed positive with 26 positive, 14 negative and 0 flat
  • 9/29 – Monday closed positive with 33 positive, 5 negative and 2 flats

Last week:

  • 9/26 – Friday closed positive with 29 positive, 9 negative and 2 flats
  • 9/25 - Thursday closed negative with 8 positive, 30 negative and 2 flat
  • 9/24 – Wednesday closed positive with 28 positive, 11 negative and 1 flat
  • 9/23 – Tuesday closed negative with 7 positive, 32 negative and 1 flat
  • 9/22 – Monday closed positive with 31 positive, 9 negative and 0 flat

 

Welcome to my world of defining the “grey’ in our universe!

  • “I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”
  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
  • I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader” – they were pretty simple instructions to follow!

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Thursday: CRISPR Therapeutics (CRSP), Sarepta Therapeutics (SRPT) and Vertex (VRTX)
  • Wednesday: IQV Holdings (IQV), Vertex (VRTX) and Alnylam Pharmaceuticals (ALNY)
  • Tuesday: IQV Holdings (IQV), Alnylam Pharmaceuticals (ALNY) and Lenz Therapeutics (LENZ)
  • Monday: Vertex (VRTX), uniQure NV (QURE) and Lenz Therapeutics (LENZ)

The worst three (3) in the session:

  • Thursday: Alnylam Pharmaceuticals (ALNY), uniQure NV (QURE) and Lenz Therapeutics (LENZ)
  • Wednesday: uniQure NV (QURE), Vericel (VCEL) and Solid Biosciences (SLDB)
  • Tuesday: Vertex (VRTX), uniQure NV (QURE) and Precigen (PGEN)
  • Monday: Cellectis SA (CLLS), BioLife Solutions (BLFS) and Solid Biosciences (SLDB)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.